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Abstract
Background: People living with HIV (PLWH) who drink alcohol and use tobacco are particularly vulnerable to
tobacco-induced diseases due to an already compromised immune system. This study investigated the prevalence
and factors associated with tobacco use (cigarette and snuff) among PLWH who drink heavily.
Methods: Participants (n = 623) on antiretroviral therapy for HIV who reported heavy drinking using the Alcohol
Use Disorders Identification Test (AUDIT) and AUDIT-C were recruited from six hospitals in Gauteng Province, South
Africa. The Fagerström test was used to assess nicotine dependence. Chi Square tests and modified Poisson
regression analyses were conducted to identify factors associated with tobacco use.
Results: Almost half of the participants reported ever smoking (44.0%; CI: 40.1–47.9) and about a quarter reported
ever using snuff (25.5%; CI: 22.2–29.1). Current smokers and current snuff users comprised 27.3% (CI: 23.9–30.9) and
19.1% (CI: 16.2–22.3) of all participants respectively. Among current smokers, 37.9% (CI: 30.8–45.3) were moderately/
highly dependent on nicotine. Current ‘any tobacco product users’ (ATPU: use cigarettes or snuff) were 45.4% (CI:
41.5–49.3) while 1.0% (CI: 0.4–2.0) currently used cigarettes and snuff. Adjusted regression analyses showed that,
compared to males, females were less at risk of being: ever smokers (Relative Risk Ratio [RRR] = 0.33; CI: 0.27–0.41),
current smokers (RRR = 0.18; CI: 0.12–0.25), and ATPU (RRR = 0.75; CI: 0.63–0.89) but were more at risk of ever snuff
use (RRR = 5.23; CI: 3.31–8.25), or current snuff use (RRR = 26.19; CI: 8.32–82.40) than males. Ever snuff users (RRR =
1.32; CI: 1.03–1.70), current snuff users (RRR = 1.40; CI: 1.03–1.89) and ATPU (RRR = 1.27; CI: 1.07–1.51) were more at
risk of reporting significant depressive symptoms. We found no significant associations between smoking status and
years on ART and viral load.
Conclusion: There is a high prevalence of cigarette and snuff use among PLWH who drink heavily. Tobacco use
cessation interventions tailored specifically for this population and according to their tobacco product of choice are
urgently needed given their vulnerability to ill-health.
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Background
Tobacco use is associated with many health conditions
including several types of cancer [1]. The average
smoker dies 10 years earlier [2] and starts to suffer dis-
ability 12 years earlier than the general population [3].
South Africa has the largest HIV epidemic globally with
19% of the global population of people living with HIV
(PLWH), 15% of new infections and 11% of global
AIDS-related deaths [4]. As of 2016, there were about 7
million PLWH in the country, with 56% having access to
antiretroviral therapy (ART) [4].
Globally, PLWH have a higher tobacco use prevalence
than the general population [5–8]. However, there is a
dearth of data on tobacco use among PLWH in low and
middle income countries [8, 9]. A case control study
conducted in South Africa involving 279 men living with
HIV and co-infected with tuberculosis (TB) reported a
33% smoking prevalence, a lower median CD4 count,
and a higher median HIV viral load among smokers
[10]. The odds of being diagnosed with TB were three
times higher for current smokers and two times higher
for former smokers compared to never smokers [10].
Another South African study found the smoking preva-
lence among a sample of 1210 PLWH to be alarmingly
high with 52% of men and 13% of women in the study
confirmed as current smokers using urine cotinine and
exhaled carbon monoxide tests [5].
PLWH already have a compromised immune system
due to their HIV status but this is worsened by the use
of tobacco products thus increasing morbidity and mor-
tality rates among this subpopulation [9, 11]. At the on-
set of the AIDS epidemic and for many years after,
Kaposi Sarcoma (KS) was the most prevalent form of
cancer among PLWH [1]. With increased access to anti-
retroviral therapy (ART), KS has become rare among
PLWH (especially in developed countries) [1] while non-
AIDS defining cancers have become more common in
this population [12]. Highly active ART has been re-
markably successful in prolonging survival among
PLWH [13]. However, tobacco use-related conditions
such as lung and oropharyngeal cancers [12], chronic
obstructive pulmonary disease, and cardiovascular dis-
ease now account for a growing proportion of morbidity
and mortality in this population [13]. A higher preva-
lence of smoking among PLWH than the general popu-
lation has led to a higher risk of lung cancer and
cardiovascular disease among PLWH [14]. Smoking is
also a risk factor for TB which is a common cause of
death among PLWH in South Africa [11].
PLWH who are heavy drinkers are at an increased risk
of a worsened course of HIV/AIDS and are less likely to
adhere to their medication [15, 16]. Alcohol use interacts
with the immune system consequently compromising it
further [15]. A study of tobacco smoking and alcohol
use among PLWH conducted in Nepal found drinking
alcohol to be more likely associated with current tobacco
smoking among PLWH [17]. A correlation between al-
cohol and tobacco use has also been found in the gen-
eral population [18]. High rates of depressive episodes
have been reported by PLWH. In a study involving 1187
PLWH in Nigeria, 28.2% of the participants were posi-
tively diagnosed with major depressive episodes [19].
Globally, there is a dearth of research on the use of to-
bacco among PLWH who drink heavily. There are a few
studies investigating tobacco use among the general
population of PLWH in South Africa and no study has
examined tobacco use among PLWH who drink alcohol.
The aim of this study is to investigate tobacco use
among a sample of PLWH who drink heavily. We exam-
ined the demographic characteristics and health out-
comes of PLWH who drink heavily and use tobacco, in
order to inform targeted and tailored tobacco use cessa-
tion interventions for this sub-population. Factors asso-
ciated with tobacco use were also explored.
Methods
Design
The methodology of the larger study has been described
in detail elsewhere [20]. This paper reports on the cross-
sectional baseline data on tobacco use and nicotine de-
pendence among people who participated in a random-
ized controlled trial testing the efficacy of an alcohol-
focused intervention to reduce alcohol consumption and
improve HIV treatment outcomes [20]. Data were col-
lected from May 2016 to October 2017 across six study
sites.
Participants and procedures
Participants for the study were recruited at ART clinics
in four district hospitals and two tertiary hospitals in the
Tshwane Metropolis, Gauteng Province in South Africa.
The province was chosen because it houses the nation’s
capital and has the highest population of all provinces,
with the most diverse demographic characteristics. The
inclusion criteria for the study sites were ART clinics
that could guarantee availability of ART for the duration
of the project and having a large active caseload of
PLWH receiving ART (e.g. at least 100 per week) to fa-
cilitate patient recruitment [20]. Participants were in-
cluded in the study if they were residing in the Tshwane
metropolis, 18 years and older, HIV positive, had been
on ART for a minimum of 3 months, not being treated
for TB, screened positive for heavy alcohol use based on
an AUDIT-C score ≥ 4 for males and ≥ 3 for females and
a total AUDIT score of < 23, and of good general health.
Participants were excluded if they were enrolled in an-
other trial. Questionnaires were administered to the par-
ticipants by trained fieldworkers in private spaces within
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the study sites, while qualified phlebotomists collected
blood to assess participants’ viral load and recent alcohol
consumption. Out of 3054 participants screened, 623
who met the eligibility criteria and consented to partici-
pate in the study were enrolled and completed baseline
assessments.
Assessment tools
This paper focuses on data collected on tobacco use,
nicotine dependence, demographic and health out-
comes (duration on ART, viral load, and depressive
symptoms). Demographic questions in the baseline as-
sessment [20] included: age, gender, marital status,
education, employment, sources of income, and
monthly income. Socioeconomic status (SES) was de-
rived from questions in an asset index. The asset
index score was based on ownership of a radio, televi-
sion, landline telephone, refrigerator, computer/laptop
and washing machine; as well as access to electricity.
Assets were assessed on the household level. The
asset index scores were categorized as: 0–2 = low SES;
3–5 = medium SES and 6–8 = high SES. Participants
were also asked to report on their use of tobacco
products (cigarette and snuff only, being the two
most common tobacco products used in South
Africa).
Tobacco use variables were classified as: ever use (ever
experimented with smoking cigarettes, even one or two
puffs or ever used snuff), current use (ever smoked ciga-
rettes, past 30 days smoking, and having smoked ≥100
sticks of cigarettes in their lifetime, or ever used snuff
and past 30 days snuff use) [21], dual tobacco product
use (being a current smoker and current snuff user) and
‘any tobacco product use’ (ATPU; being a current
smoker or snuff user).
Nicotine dependence was assessed only for cigarette
smokers using the Fagerstrom Test for Nicotine De-
pendence (FTND) [22]. The FTND is a scale comprising
six questions with the total score for the scale catego-
rized as 7–10 (highly dependent); 4–6 (moderately
dependent), and 0–3 (minimally dependent) [14]. The
FTND scores were recategorized by merging ‘moder-
ately’ and ‘highly dependent’ categories to form a ‘mod-
erately/highly dependent’ category. Viral load (VL) was
determined by a laboratory test while years on ARVs
were self-reported. VL was categorized as: low VL (0–10,
000); moderate VL (10,001-50,000) and high VL (> 50,
000). A short version of the Center for Epidemiological
Studies Depression measure with 10 questions (CES-D-
10) [23] was used to collect data on depressive symp-
toms. The scale scores were categorized as ≥10 (signifi-
cant depressive symptoms) and < 10 (non-significant
depressive symptoms). The CES-D-10 has been previ-
ously validated for use in South Africa [24].
Data analysis
Stata version 14.0 [25] was used to perform all the ana-
lyses. Cross-tabulation and Chi-square tests were used
to assess the percentages and gender differences in par-
ticipants’ tobacco use, nicotine dependence, and report
of depressive symptoms. Unadjusted and adjusted modi-
fied Poisson regression analyses were performed to as-
sess relationships between demographic characteristics,
health outcomes and tobacco indicators). Variables
which had categories that were significant (p ≤ .05) in
the unadjusted modified Poisson regression tests were
included in the multiple regression models (modified
Poisson regression) to identify the factors associated
with tobacco use in this population. The p-value ≤ .05
was considered statistically significant for all analyses.
Only a small proportion of the participants had missing
data, and these were excluded on a case by case basis in
all analyses (i.e. missing data were excluded for each
analysis for all the statistical tests conducted). In Tables 1
and 2, the number of participants included in each ana-
lysis is specified.
Results
Demographic characteristics of participants
Just over half of the participants in our study were fe-
male (57.5%) (Table 1). The largest group of participants
(44.6%) were between 35 and 44 years old. About 94% of
the participants reported either medium or high socio-
economic status (SES) in almost equal proportions. Just
over half of the participants (52.7%) have never been
married and slightly above 40% were unemployed. Only
13.0% of the participants had attained post-secondary
education (> Grade 12). Almost half of the participants
had been on ARVs for at least 7 years. More than 90%
had low viral loads at the time of collecting baseline in-
formation. Almost half of all participants (46.4%) re-
ported having significant depressive symptoms.
Tobacco use among PLWH who drink heavily
The prevalence of ever smoking and ever using snuff in
this study was 44.0% (n = 274) and 25.5% (n = 159), re-
spectively (Table 2). Of participants who had ever
smoked, 68.2% (n = 180) initiated smoking by the age of
20 while 88.3% (n = 233) had tried smoking by the age of
25. Current smokers comprised 27.3% (n = 170) and
current snuff users comprised 19.1% (n = 119) of all par-
ticipants. One percent of the participants smoked ciga-
rettes and used snuff (dual users) while almost half of
the sample (45.4%, n = 294) reported either currently
smoking cigarettes or using snuff (ATPU). Among
current smokers, 37.9% (n = 65) were moderately/highly
dependent on nicotine according to the FTND.
Chi square tests exploring gender and tobacco use be-
haviour (Table 2) showed significant differences between
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males and females with regards to ever smoking, current
smoking, ever snuff use, current snuff use and ATPU.
No significant gender differences emerged for the age of
first use, nicotine dependence, and dual product use
(Table 2).
Relationship between tobacco use, demographic
characteristics and depression among PLWH who drink
heavily
In unadjusted modified Poisson regression analyses, fe-
males showed decreased risk of being ever smokers
(RRR = 0.33; CI: 0.27–0.40), current smokers (RRR =
0.17; CI: 0.12–0.24), and ATPU (RRR = 0.76; CI: 0.64–
0.90) and increased risk of being ever and current snuff
users (RRR = 5.45; CI: 3.47–8.58 and RRR = 28.62; CI:
9.19–89.14 respectively) compared to males (Table 3).
Participants aged between 45 and 54 years were two
times more at risk of being ATPU (RRR = 2.37; CI: 1.08–
5.24) compared to those aged 18–24 years. Participants
aged between 55 and 65 years were three times more at
risk of being current smokers (RRR = 3.07; CI: 1.01–
9.35) and ATPU (RRR = 2.76; CI: 1.23–6.22) compared
to those aged 18–24 years. Compared to participants
reporting low SES, participants of high SES were less
likely to be current smokers (RRR = 0.61; CI: 0.39–0.97).
Also, participants who were never married showed less
risk of being ever smokers (RRR = 0.79; CI: 0.65–0.96)
and more risk of being current snuff users (RRR = 1.65;
CI: 1.07–2.54) compared to those who were married.
Participants who were employed were more at risk of
being ever smokers (RRR = 1.28; CI: 1.06–1.54) but were
less at risk of being current snuff users (RRR = 0.75; CI:
0.57–0.97) compared to those participants who were
unemployed.
Investigation of participants’ highest educational at-
tainment and their tobacco use status showed that
PLWH who attained Grade 12 or a post-secondary edu-
cation (> Grade 12) were less at risk of being ever snuff
users (RRR = 0.55, CI: 0.37–0.80; RRR = 0.56, CI: 0.34–
0.93), current snuff users (RRR = 0.50, CI: 0.32–0.80;
RRR = 0.47, CI: 0.25–0.89) and ATPU (RRR = 0.64, CI:
0.51–0.82; RRR = 0.74, CI: 0.55–0.99) compared to those
who attained less than Grade 12 education. However,
participants who reported having significant depressive
symptoms showed more risk of being ever snuff users
(RRR = 1.55; CI: 1.18–2.03), current snuff users (RRR =
1.71; CI: 1.23–2.38) and ATPU (RRR = 1.29; CI: 1.08–
1.53) compared to those who reported insignificant de-
pressive symptoms.
Factors associated with tobacco use among PLWH who
drink heavily
Multiple Modified Poisson Regression analyses were
conducted to determine the factors associated with to-
bacco use (Table 4). Adjusted relative risk ratios are re-
ported in this section.
Compared to males, females were less at risk of being
ever smokers (RRR = 0.33; CI: 0.27–0.41), current
smokers (RRR = 0.18; CI: 0.12–0.25) and ATPU (RRR =
0.75; CI: 0.63–0.89) but more at risk of being ever snuff
Table 1 Demographics and health outcomes of study
participants
Variable n(N = 623) % (CI)
Gender
Male 265 42.5 (38.7–46.5)
Female 358 57.5 (53.5–61.3)
Age
18–24 23 3.7 (2.5–5.5)
25–34 118 18.9 (16.1–22.2)
35–44 278 44.6 (40.7–48.6)
45–54 155 24.9 (21.6–28.4)
55–65 45 7.2 (5.4–9.6)
65+ 4 0.6 (0.2–1.7)
Socioeconomic status
Low 36 5.8 (4.2–7.9)
Average 293 47.0 (43.1–51.0)
High 294 47.2 (43.3–51.1)
Marital Status
Married 173 27.8 (24.4–31.4)
Cohabiting 55 8.8 (6.8–11.3)
Never married 328 52.7 (48.7–56.6)
DIV, SEP and WID 67 10.8 (8.5–13.5)
Employment
Unemployed 254 42.4 (38.5–46.3)
Employed 359 57.6 (53.7–61.5)
Education
< Grade 12 383 86.5 (57.6–65.2)
Grade 12 159 25.5 (22.2–29.1)
> Grade 12 81 13.0 (10.6–15.9)
Years on ARV
Less than one year 27 4.4 (3.0–6.3)
1–3 years 115 18.6 (15.7–21.8)
4–6 years 172 27.8 (24.4–31.5)
7 years and more 305 49.3 (45.3–53.2)
Viral Load
Low VL 539 92.3 (89.9–94.2)
Moderate VL 25 4.3 (2.9–6.3)
High VL 20 3.4 (2.2–5.3)
Depression
Non-significant symptoms 334 53.6 (49.7–57.5)
Significant symptoms 289 46.4 (42.5–50.3)
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users (RRR = 5.23; CI: 3.31–8.25) and current snuff users
(RRR = 26.19; CI: 8.32–82.40). Compared to partici-
pants who had not completed Grade 12, participants
who attained Grade 12 or a post-secondary education
were less at risk of being ever snuff users (RRR = 0.61;
CI: 0.42–0.88 and RRR = 0.61; CI: 0.37–0.98) and
current snuff users (RRR = 0.57; CI: 0.37–0.89 and
RRR = 0.51; CI: 0.27–0.93). However, only participants
who had completed Grade 12 were less at risk of
using any tobacco products (RRR = 0.68; CI: 0.53–
0.86). Participants who reported significant depressive
symptoms were more at risk of being ever and
current snuff users and ATPU (RRR = 1.32, CI: 1.03–
1.70; RRR = 1.40; CI: 1.03–1.89 and RRR = 1.27, CI:
1.07–1.51 respectively). In terms of age, participants
aged between 55 and 64 years were more at risk of
reporting any tobacco product use (RRR = 2.25; CI:
1.01–5.03) compared to those aged between 18 and
24 years.
Discussion
The smoking prevalence found in our study (27%) is
higher than the smoking prevalence in the general popu-
lation of South Africa which is about 22% (among those
aged 15+ years) according to the 2016 South African
Demographic and Health Survey (SADHS) [26]. In our
study, the prevalence of ATPU (45%) is almost twice as
high as for the general population (25%) [26], while
more than half of the men in our study currently smoke.
A study of smoking among 1210 PLWH conducted in
Klerksdorp (in the North West Province of South Africa)
also found a current smoking prevalence of about 25%
based on self-report and 28% based on exhaled carbon
monoxide and urine cotinine tests [5]. The self-reported
Table 2 Tobacco use by gender among PLWH who drink heavily in South Africa
Variable (n) Male % (CI) Female % (CI) Total p*
Ever smoking (N = 623)a < 0.001
Yes (274) 71.3 (65.6–76.5) 23.7 (19.6–28.4) 44.0 (40.1–47.9)
No (349) 28.7 (23.5–34.4) 76.3 (71.5–80.4) 56.0 (52.1–59.9)
Age of first try (N = 264)b 0.152
6–15 years (59) 26.1 (20.2–32.7) 13.2 (7.0–22.1) 22.4 (17.6–27.7)
16–20 years (121) 44.2 (37.2–51.3) 50.0 (38.9–61.1) 45.8 (39.9–51.9)
21–25 years (53) 18.1 (13.1–24.1) 25.0 (16.3–35.5) 20.1 (15.6–25.2)
26–30 years (20) 6.9 (3.9–11.2) 9.2 (4.2–17.2) 7.6 (4.8–11.2)
31+ years (11) 4.8 (2.4–8.5) 2.6 (0.6–8.2) 4.2 (2.2–7.1)
Current cigarette smoking (N = 623)a < 0.001
Yes (170) 52.1 (46.1–58.0) 8.9 (6.4–12.4) 27.3 (23.9–30.9)
No (453) 47.9 (42.0–54.0) 91.1 (87.6–93.6) 72.7 (69.1–76.1)
Nicotine dependence (N = 170)c 0.096
Minimally dependent (106) 59.1 (50.7–67.1) 75.0 (57.3–87.1) 62.1 (54.7–69.2)
Moderately/Highly dependent (64) 40.9 (32.9–49.4) 25.0 (13.0–42.7) 37.9 (30.8–45.3)
Ever snuff use (N = 623)a < 0.001
Yes (159) 7.2 (4.5–10.8) 39.1 (34.2–44.2) 25.5 (22.2–29.1)
No (464) 92.8 (89.3–95.5) 60.9 (55.8–65.8) 74.4 (71.0–77.8)
Current snuff use (N = 623)a < 0.001
Yes (119) 1.1 (0.3–3.0) 32.4 (27.7–37.4) 19.1 (16.2–22.3)
No (504) 98.9 (97.0–99.7) 67.6 (62.6–72.3) 80.9 (77.7–83.8)
Dual Tobacco use (N = 623)a 0.198
Yes (6) 0.4 (0.1–2.6) 1.4 (0.6–3.3) 1.0 (0.4–2.0)
Any tobacco product Use (N = 623)a 0.001
Yes (294) 52.8 (46.8–58.8) 39.9 (35.0–45.1) 45.4 (41.5–49.3)
No (329) 47.2 (41.2–53.2) 60.1 (54.9–65.0) 54.6 (50.7–58.5)
abaseline: overall sample
bbaseline: ever smokers
cbaseline: current smokers
*Chi Square test with p significant at ≤ .05
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Table 4 Adjusted modified Poisson regression investigating factors associated with tobacco use behaviour
Dependent variable Covariates RRR 95% CI p
Ever smoking Gender
Male 1
Female 0.33 0.27–0.41 < 0.001*
Marital Status
Married 1
Cohabiting 0.95 0.73–1.24 0.703
Never married 0.98 0.82–1.17 0.822
Othera 0.95 0.71–1.28 0.753
Employment
Unemployed 1
Employed 1.01 0.85–1.20 0.883
Current smoking Gender
Male 1
Female 0.18 0.12–0.25 < 0.001*
Age
18–24 1
25–34 1.99 0.67–5.90 0.217
35–44 1.74 0.60–5.05 0.306
45–54 1.79 0.62–5.17 0.282
55–64 2.04 0.69–5.99 0.195
65+ 1.15 0.18–7.16 0.882
SES
Low± 1
Average 0.92 0.66–1.29 0.641
High 0.78 0.55–1.11 0.165
Employment
Unemployed 1
Employed 1.02 0.79–1.31 0.911
Ever snuff use Gender
Male 1
Female 5.23 3.31–8.25 < 0.001*
Employment
Unemployed 1
Employed 1.05 0.81–1.34 0.731
Education
< Grade 12 1
Grade 12 0.61 0.42–0.88 0.008*
> Grade 12 0.61 0.37–0.98 0.043*
Depression
Non-significant symptoms 1
Significant symptoms 1.32 1.03–1.70 0.032*
Current snuff use Gender
Male 1
Female 26.19 8.32–82.40 < 0.001*
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prevalence rate is slightly lower than what we found in
our study. This is also the case with the pooled smoking
prevalence among HIV positive men in 28 LMICs (24%)
by Mdege and colleagues [9]. Since our study focused
only on PLWH who are heavy alcohol drinkers, the
higher smoking prevalence found in our study is likely
to be due to the close association between alcohol use
and smoking reported by several studies both in South
Africa and globally [5, 17, 18, 27].
As tobacco use carries many health risks including
causing various cancers and cardiovascular diseases, the
higher prevalence of its use among PLWH who already
have a compromised immune system and who are heavy
alcohol drinkers is worrisome. As mentioned earlier, the
co-use of tobacco and alcohol is common in society [28,
29] and both substances are known to have reciprocal
influences on each other [30, 31]. Studies have shown
specific negative effects of tobacco use on PLWH includ-
ing decreased neurocognitive functioning, impaired T-
Cells functioning, increased susceptibility to the known
effects of smoking, reduced ART adherence and prob-
lematic alcohol use [28, 32–34]. Alcohol use in itself is
Table 4 Adjusted modified Poisson regression investigating factors associated with tobacco use behaviour (Continued)
Dependent variable Covariates RRR 95% CI p
Marital Status
Married 1
Cohabiting 1.10 0.60–2.01 0.770
Never married 1.24 0.83–1.84 0.293
Othera 1.26 0.75–2.11 0.392
Employment
Unemployed 1
Employed 1.01 0.75–1.36 0.958
Education
< Grade 12 1
Grade 12 0.57 0.37–0.89 0.012*
> Grade 12 0.51 0.27–0.93 0.029*
Depression
Non-significant symptoms 1
Significant symptoms 1.40 1.03–1.89 0.030*
Any tobacco product use Gender
Male 1
Female 0.75 0.63–0.89 0.001*
Age
18–24 1
25–34 1.64 0.75–3.61 0.217
35–44 2.01 0.93–4.34 0.074
45–54 2.05 0.94–4.47 0.070
55–64 2.25 1.01–5.03 0.047*
65+ 1.07 0.18–6.36 0.943
Education
< Grade 12 1
Grade 12 0.68 0.53–0.86 0.001*
> Grade 12 0.80 0.60–1.07 0.132
Depression
Non-significant symptoms 1
Significant symptoms 1.27 1.07–1.51 0.005*
RRR Adjusted Relative Risk Ratio based on modified Poisson regression
a“other” marital status includes divorced, separated, or widowed
*significant at p ≤ .05
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known to affect HIV treatment outcomes and contribute
to poor adherence to ART [35–37]. When PLWH use
both alcohol and tobacco, this further compromises their
immune systems and may result in even worse HIV
treatment outcomes than if they only used one sub-
stance. The interaction effect of the co-use of alcohol
and tobacco is not well researched [38]. However, Peluc-
chi and colleagues found that the co-use of alcohol and
tobacco increases the risk of aerodigestive tract and liver
cancers in the general population [38].
Another consequence of the co-use of alcohol and to-
bacco is the economic implication of using these two ad-
dictive substances for the person who is resource-
constrained. In this study, participants with high SES
were less likely to be current smokers although this as-
sociation was not significant after controlling for gender,
age and employment status. This finding however im-
plies that some smokers in this population will need to
use their limited resources to cater for their smoking
and alcohol use. Also, low educational attainment (not
completing Grade 12) was found to be associated with
both ever and current snuff use in this study. There is a
high likelihood that persons with low educational quali-
fications earn lower salaries. The limited availability of
funds among such populations would make it even more
costly to maintain their tobacco or alcohol use, further
straining household finances.
The high prevalence of tobacco use among PLWH
who drink heavily in this study also makes it imperative
that tobacco use cessation interventions combined with
interventions to curb heavy drinking are urgently pro-
vided for this population. Specifically, there is need to
introduce screening for tobacco and alcohol use as
PLWH are initiated onto ART. This screening should be
accompanied by targeted tobacco use cessation interven-
tions and education on the harm of tobacco use, includ-
ing the use of snuff. These interventions are urgently
needed for PLWH in South Africa [39]. As we found
that most of the participants who smoke cigarettes were
minimally dependent on nicotine, there is a high prob-
ability of tobacco use interventions being successful in
this population.
If this problem does not receive attention, more
PLWH may die early of tobacco-related diseases espe-
cially if they also drink heavily. A delay in rolling out
these interventions could lead to a reversal of the pro-
gress already made in the fight against HIV.
The 2012 US Surgeon General’s report highlighted
that 99% of adults who are daily smokers had already
initiated smoking by the time they were 26 years of age
[40]. As such, our findings that almost 70% of PLWH
had initiated tobacco use by the age of 20 is not a sur-
prise. Given the early age of initiation, education about
the health hazards associated with tobacco use is
especially important for PLWH who are adolescents and
young adults since most smokers begin before age 18
[41]. Such interventions should include information on
the possible effects of using tobacco on HIV treatment
outcomes. Interventions like this will help to discourage
the initiation of tobacco use by PLWH who have not yet
started using tobacco and would encourage those who
have already initiated tobacco use to quit.
Snuff use is associated with various types of cancer
[42] including head, neck and oral cancers [43–45] and
was found to be positively associated with a TB diagno-
sis among women living with HIV in South Africa [46].
Similar to our findings, a previous study found that fe-
males use snuff more than males in the general popula-
tion [5], while a study among PLWH found an
extremely high (49%) prevalence of snuff use among
women living with HIV in South Africa [46]. The high
prevalence of snuff use found among women in this
study also confirms the need for targeted awareness and
cessation interventions. While intervention for men who
use tobacco could focus more on cigarettes and other
combustible tobacco products, those for women who
use tobacco should focus more on snuff use and other
smokeless tobacco products.
Nicotine dependence was only investigated for
cigarette smokers in this study. Future studies should
use the FTND for smokeless tobacco users to ascertain
nicotine dependence among smokeless tobacco users to
better understand nicotine dependence among all to-
bacco product users.
A Nigerian study of 1187 PLWH found more than a
quarter of the participants diagnosed with major depres-
sive episodes based on the Diagnostic and Statistical
Manual of Mental Disorders (DSM)-IV diagnostic cri-
teria [19]. In our study, only snuff use was found to be
significantly associated with depressive symptoms. The
relationship between depression and snuff use found in
this study is of concern. There is need to further explore
this link in order to understand why more snuff users
reported having moderate to high levels of depressive
symptoms.
Limitations
In this study, tobacco use was self-reported which could
lead to participants giving socially desirable answers.
Also, self-reported tobacco use status was not confirmed
using exhaled carbon monoxide or urine cotinine tests.
The findings may also not be generalizable to PLWH at-
tending HIV clinics outside of the Tshwane metropolis.
Nicotine dependence was only investigated for cigarette
smokers in this study, therefore, our understanding of
nicotine dependence in this population is limited consid-
ering the high prevalence of snuff users found in this
study.
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Conclusion
The co-use of alcohol and tobacco is problematic for the
general population and even more problematic for the
health of PLWH. A better understanding of the tobacco
use culture among PLWH is needed to inform interven-
tions targeted for this population. For this population,
information on the reasons for initiating tobacco use,
when and why tobacco use was initiated, type of tobacco
product used, intention to quit, barriers and access to
tobacco use cessation interventions is needed [29]. Tar-
geted cessation interventions, including combination
therapy involving both pharmacological and psycho-
logical interventions, should be explored to help PLWH
who use tobacco to quit. In this region, men may benefit
from interventions tailored to address cigarette use,
whereas women could benefit from interventions that
focus on snuff use.
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